We are very much interested in making sure that payers (support) newborn screening, that they establish fast turnaround on coverage decisions, and that they have specific policies that cover gene therapy for SMA, as we negotiate discounts, et cetera, with payers, and the contracts with those payers, we're trying to make sure they put those elements in place.